John L. Marshall, MD, discusses highlights from several of the key studies presented at the 2008 Annual Meeting of the American Society of Clinical Oncology, including advances in the role of biomarkers in gastrointestinal cancer treatment efficacy.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss the role of KRAS mutations in epidermal growth factor receptor–targeted therapies for patients with colorectal cancer
• Describe recent clinical trial results related to adjuvant chemotherapy in colorectal cancer
• Explain the efficacy of dual antibody therapy in the treatment of refractory and frontline metastatic colorectal cancer
• Review the role of positron emission tomography in patient selection for surgical resection of metastatic colorectal cancer